Athersys enrolls first patients in MultiStem cell therapy study to combat coronavirus-induced ARDS

Athersys, Inc.

Athersys Inc. (NASDAQ: ATHX) of Cleveland announced on Tuesday, May 5, that the first patients have been enrolled in a clinical trial of its MultiStem cell therapy for acute respiratory distress syndrome (ARDS) caused by the coronavirus.

The patients for the Phase 2/3 study, called MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome (MACOVIA), were enrolled at University Hospitals Cleveland Medical Center. Athersys said in a news release that Medpace, based in Cincinnati, is serving as the contract research organization for the study.

Click here to read the complete story.

Story excerpt provided by Crains Cleveland Business.

Written by Scott Suttell.

Originally published May 5, 2020.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: